501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro. Issue 1 (1st January 2021)

• Record Type: Journal Article
• Authors: Liu, Haolin; Wei, Pengcheng; Zhang, Qianqian; Chen, Zhongzhou; Aviszus, Katja; Downing, Walter; Peterson, Shelley; Reynoso, Lyndon; Downey, Gregory P.; Frankel, Stephen K.; Kappler, John; Marrack, Philippa; Zhang, Gongyi
• Is Part Of: MAbs. Volume 13:Issue 1(2021)
• Publication Date: 2021-01-01
• Subjects: SARS-COV-2 -- COVID-19 -- B.1.1.7/501Y.V1 -- B.1.351/501Y.V2 -- P.1/501Y.V3 -- ACE2 -- RBD; Bamlanivimab; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2021.1919285
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: The newly emerging variants of SARS-CoV-2 from South Africa (B.1.351/501Y.V2) and Brazil (P.1/501Y.V3) have led to a higher infection rate and reinfection of COVID-19 patients. We found that the mutations K417N, E484K, and N501Y within the receptor-binding domains (RBDs) of the virus could confer ~2-fold higher binding affinity to the human receptor, angiotensin converting enzyme 2 (ACE2), compared to the wildtype RBD. The mutated version of RBD also completely abolishes the binding of bamlanivimab, a therapeutic antibody, in vitro . Detailed analysis shows that the ~10-fold gain of binding affinity between ACE2 and Y501-RBD, which also exits in the high contagious variant B.1.1.7/501Y.V1 from the United Kingdom, is compromised by additional introduction of the K417/N/T mutation. Mutation of E484K leads to the loss of bamlanivimab binding to RBD, although this mutation does not affect the binding between RBD and ACE2.